Formation and Biological Properties of Neutrophil Activating Peptide 2 (NAP-2)
Neutrophil-activating peptide 2 (NAP-2) was isolated from stimulated cultures of human blood mononuclear cells (1). NAP-2 consists of 70 amino acids and is structurally related to NAP-1/IL-8 (2), a peptide produced by a variety of cells upon induction with interleukin-1 or tumor necrosis factor alpha (3), and to melanoma growth-stimulatory activity (MGSA) which was shown to be mitogenic for cultured human melanoma cells (4, 5). NAP-1/IL-8 and MGSA are potent chemotactic agents for human neutrophils in vitro and in vivo (6, 7), and induce cytosolic free calcium changes, the respiratory burst and exocytosis (8). The amino acid sequence of NAP-2 corresponds to part of the sequence of platelet basic protein (PBP) (9) and its derivative, connective tissue activating peptide III (CTAP-III, ref 10) and to other inactive cleavage products which were recently identified (11). NAP-2 also shows structural homology to platelet factor 4 (PF-4), another peptide contained in the platelet alpha granules (12).
KeywordsHuman Neutrophil Respiratory Burst Adult Respiratory Distress Syndrome Platelet Factor Lower Dermis
Unable to display preview. Download preview PDF.
- 5.Richmond A., E. Balentien, H.G. Thomas, G. Flaggs, D.E. Barton, J. Spiess, R. Bordoni, U. Francke, and R. Derynck. 1988. Molecular characterization and chromosomal mapping of melanoma growth stimulatory activity, a growth factor structurally related to β-thromboglobulin. EMBO J. 7: 2025–2033.PubMedGoogle Scholar
- 17.Schroeder J.M., U. Mrowietz, E. Morita, and E. Christophers. 1987. Purification and partial characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity. J. Immunol. 139: 3474–3483.Google Scholar
- 18.Walz A., B. Dewald, and M. Baggiolini. 1990. Formation and biological activity of NAP-2, a neutrophil-activating peptide derived from platelet α-granule precursors, in: Molecular and cellular biology of cytokines edited by J.J. Oppenheim, M.C. Powanda, M.J. Kluger and C.A. Dinarello. Alan A. Liss, Inc., New York, in press.Google Scholar
- 21.Lindley I., H. Aschauer, J.M. Seiffert, C. Lam, W. Brunowsky, E. Kownatzky, M. Thelen, P. Peveri, B. Dewald, V. von Tscharner, A. Walz, and M. Baggiolini. 1988. Synthesis and expression in Escherichia coli of the gene encoding monocyte-derived neutrophil-activating factor: biological equivalence between natural and recombinant neutrophil-activating factor. Proc. Natl. Acad. Sci. USA 85: 9199–9202.PubMedCrossRefGoogle Scholar
- 22.Wachtvogel Y.T., U. Kucich, J. Greenplate, P. Gluszko, W. Abrams, G. Weinbaum, R.K. Wenger, B. Rucinski, S. Niewiaroski, L.H. Edmunds Jr., et al. 1987. Human neutrophil degranulation during extracorporeal circulation. Blood 69: 324–330.Google Scholar
- 23.Van Oeveren W., M.D. Kazatchkine, B. Descamps-Latscha, F. Maillet, E. Fischer, A. Carpentier, and C.R. Wildevuur. 1985. Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. J. Tliorac. Cardiovasc. Surg. 89: 888–899.Google Scholar